5-hydroxyflunixin: drug residue in cow milk [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 12978215 |
| MeSH ID | M0536461 |
| Synonym |
|---|
| FT-0669638 |
| 75369-61-8 |
| 5-hydroxy flunixin (contain 5% flunixin) |
| 5-hydroxyflunixin |
| 5-hydroxy-2-(2-methyl-3-trifluoromethylanilino) nicotinic acid |
| 5-hydroxy-2-[2-methyl-3-(trifluoromethyl)anilino]pyridine-3-carboxylic acid |
| DTXSID60514274 |
| 5-hydroxy flunixin |
| 5-hydroxyflunixin, vetranal(tm), analytical standard |
| AKOS030242943 |
| Q63409161 |
| 5-hydroxy-2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinic acid |
| flunixin-5-hydroxy 100 microg/ml in acetonitrile |
| 5-hydroxy flunixin is known as a flunixin metabolite. |
| PD150652 |
| 5-hydroxy-2-((2-methyl-3-(trifluoromethyl)phenyl)amino)nicotinicacid |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The mean bioavailability following intramuscular and subcutaneous dosing was 84." | ( Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. Baynes, RE; Kissell, LW; Leavens, TL; Riviere, JE; Smith, GW; Wu, H, 2012) | 0.38 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The milk was collected 12h after dosing from cows which received meloxicam (0." | ( In-house reference materials: 5-hydroxyflunixin and meloxicam in cow milk-preparation and evaluation. Jedziniak, P; Olejnik, M; Szprengier-Juszkiewicz, T, 2009) | 0.64 |
| " The mean bioavailability following intramuscular and subcutaneous dosing was 84." | ( Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. Baynes, RE; Kissell, LW; Leavens, TL; Riviere, JE; Smith, GW; Wu, H, 2012) | 0.38 |
| " The highest flunixin concentration in milk was observed 12 h after dosing (2." | ( Identification of flunixin glucuronide and depletion of flunixin and its marker residue in bovine milk. Jedziniak, P; Kaczmarowski, M; Olejnik, M; Smulski, S; Szprengier-Juszkiewicz, T; Żmudzki, J, 2013) | 0.39 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.98) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (20.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||